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Aims Current treatments of ventricular arrhythmias rely on modulation of cardiac electrical function through drugs, abla-
tion or electroshocks, which are all non-biological and rather unspecific, irreversible or traumatizing interventions.
Optogenetics, however, is a novel, biological technique allowing electrical modulation in a specific, reversible and
trauma-free manner using light-gated ion channels. The aim of our study was to investigate optogenetic termination




Systemic delivery of cardiotropic adeno-associated virus vectors, encoding the light-gated depolarizing ion channel
red-activatable channelrhodopsin (ReaChR), resulted in global cardiomyocyte-restricted transgene expression in
adult Wistar rat hearts allowing ReaChR-mediated depolarization and pacing. Next, ventricular tachyarrhythmias
(VTs) were induced in the optogenetically modified hearts by burst pacing in a Langendorff setup, followed by pro-
grammed, local epicardial illumination. A single 470-nm light pulse (1000 ms, 2.97 mW/mm2) terminated 97% of
monomorphic and 57% of polymorphic VTs vs. 0% without illumination, as assessed by electrocardiogram record-
ings. Optical mapping showed significant prolongation of voltage signals just before arrhythmia termination.
Pharmacological action potential duration (APD) shortening almost fully inhibited light-induced arrhythmia termin-
ation indicating an important role for APD in this process.
...................................................................................................................................................................................................
Conclusion Brief local epicardial illumination of the optogenetically modified adult rat heart allows contact- and shock-free termin-
ation of ventricular arrhythmias in an effective and repetitive manner after optogenetic modification. These findings could
lay the basis for the development of fundamentally new and biological options for cardiac arrhythmia management.
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Introduction
Ventricular arrhythmias are a large and growing problem worldwide,
with high annual mortality and morbidity rates.1 Despite significant
progress in therapeutic strategies, the current treatment options for
ventricular arrhythmias remain suboptimal. In brief, drug treatment is
rather ineffective, while catheter ablation may cause irreversible
complications and generally has a modest long-term efficiency.
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Electroshock therapy, on the other hand, is effective in terminating
ventricular arrhythmias and has shown to reduce mortality as repre-
sented by the implantable cardiac defibrillator (ICD). However, the
high-voltage shocks delivered by these devices are traumatizing, espe-
cially when given inappropriately, as they are associated not only with
severe pain, anxiety and depression,2 but also with myocardial tissue
damage.3
In contrast, optogenetics is an emerging biological technique to
electrically modulate cells, tissue and organs in a specific, reversible
and shock-free manner using light-gated ion channels.4 Thus, optoge-
netics may provide a new incentive for the development of biological
and pain-free treatment options for cardiac arrhythmias. Recent stud-
ies have shown that cardiac optogenetics allows for optical pacing of
the whole heart and light-induced arrhythmia termination in cell cul-
tures.5–8 The aim of our present study was to investigate whether
optogenetic modification of the adult rat heart would enable light-
mediated termination of ventricular arrhythmias.
Methods
Experimental procedures are described in detail in Supplementary material
online, Supplementary material.
Animal studies
All animal experiments were approved by the Animal Experiments
Committee of the Leiden University Medical Centre and conformed to
the Guide for the Care and Use of Laboratory Animals as stated by the
US National Institutes of Health.
Optogenetic pacing and arrhythmia
termination
Four to six weeks after systemic injection of cardiotropic adeno-
associated virus (AAV) vectors encoding red-activatable channelrhodop-
sin (ReaChR),9 the hearts of anesthetized adult Wistar rats were rapidly
excised, cannulated and subsequently perfused using a Langendorff-
apparatus (n = 8). Optical pacing was performed by exposure for 20 ms
to 470-nm light-emitting diode (LED) light. Ventricular tachyarrhythmia’s
(VTs) were induced by irregular electrical burst pacing protocols with a
cycle length varying between 20 and 80 ms. When the VTs lasted for at
least 5 s, they were considered sustained and the hearts were subse-
quently exposed to a 1000-ms light pulse. VTs were considered to be
optogenetically terminated when ventricular arrhythmias stopped within
2 s after the start of illumination. When optogenetic termination failed, bi-
polar electrical defibrillation was performed (20 ms, 80 V, 12 mA). To
evaluate the effect of action potential duration (APD) shortening on
optogenetic terminaton efficiency, 3 ml of 10 mM of the KATP channel
opener P1075 was directly injected into the aortic cannula. Following an
incubation period of 1 min, the hearts were subjected to the same ar-
rhythmia induction and optogenetic termination protocol as used prior
to P1075 infusion. P1075 was considered washed out after 15 min follow-
ing administration as APD was then normalized to standard values.
Results
Systemic delivery of cardiotropic AAV vectors encoding ReaChR re-
sulted in widespread transduction of the cardiomyocytes in adult rat
hearts with an average transduction rate of 93% (SD 4%) (Figure 1A).
Functionality of these light-gated depolarizing ion channels was con-
firmed by sharp-electrode measurements in cardiac tissue slices, re-
vealing significant and sustained depolarization of the membrane
potential during 470-nm LED illumination for 1000 ms (Figure 1B).
Upon excision and preparation of the hearts in the Langendorff
setup for stimulation and readout (Figure 1C), part of the epicardial
surface was exposed to short (i.e. 20-ms) 470-nm light pulses
(0.97 mW/mm2). This allowed optical pacing up to 4.5 Hz, thereby
producing QRS complexes similar to those induced by electrical
stimulation (Figure 1D). Following the induction of sustained VTs by
electrical burst pacing, a single 470-nm light pulse (1000 ms,
2.97 mW/mm2) was given illuminating circa 125 mm2 of the ventricu-
lar surface. Such pulses led to an average successful arrhythmia ter-
mination rate of 97% for monomorphic VTs (corresponding to 26
VTs in 8 hearts) and 57% of polymorphic VTs (corresponding to 19
VTs in 6 hearts). (Supplementary material online, Video S1). Without il-
lumination, none of these arrhythmias were terminated (n = 6 for
both mono- and polymorphic VTs) (Figure 1E and F).
Optical voltage mapping was performed in order to obtain more
mechanistic insight into light-induced arrhythmia termination.
Activation maps confirmed global high-frequency activation of the
ventricles resembling reentrant activity (Figure 1G). Optical record-
ings showed that the 1000-ms light pulses resulted in arrhythmia ter-
mination within 420.9 ms (SD 189.7 ms, range 185–734 ms).
Furthermore, based on the optical signals, significant prolongation of
APD was noted just before arrhythmia termination (58.6 ms (SD
7.3 ms) vs. 72.3 ms (SD 16.3 ms) for APD80 before and during illumin-
ation, P = 0.021, n = 7). (Figure 1H and I). As this finding indicated an
important role for APD prolongation in optogenetic arrhythmia ter-
mination in these hearts, we next evaluated the effects of APD
shortening on termination efficiency. For this purpose, the optoge-
netically modified hearts were treated with a single bolus of P1075, a
KATP channel opener (n = 2). As a result, APD80 during the arrhyth-
mia was significantly shortened (62.9 ms (SD 11.8 ms) vs. 44.0 ms (SD
13.7 ms) before and after P1075 administration, P = 0.018). Using the
same arrhythmia induction and optogenetic termination protocol,
none of monomorphic VTs (0 out of 5) and only 1 out of 9 (11%)
polymorphic VTs could be terminated. After a washout period of
15 min, and normalization of APD80, optogenetic termination effi-
ciency increased to 80% for monomorphic VTs (4 out of 5) and 71%
for polymorphic VTs (5 out of 6) (Figure 1J).
Discussion
Here, we demonstrate that forced expression of a light-gated depola-
rizing ion channel (ReaChR) in the adult rat heart allows contact- and
shock-free termination of VTs through brief local illumination of the
ventricular surface, i.e. without relying on conventional drugs, tissue
ablation or electroshocks. Both mono- and polymorphic VTs could
be terminated in an effective and repetitive manner by a light-induced
electrical current driven by natural electrochemical gradients, provid-
ing proof-of-concept for biological arrhythmia termination.
The unique properties of optogenetics make it possible to modu-
late cardiac electrical activity by applying depolarizing or hyperpola-
rizing photocurrents with high specificity and unmatched
spatiotemporal precision.4 The finding that optogenetic arrhythmia







niversiteit Leiden / LU
M
C
 user on 07 January 2021
Figure 1 (A) Mid-ventricular transversal slice of an adult rat heart transduced with a cardiotropic AAV vector encoding ReaChR fused to citrine
showing global transgene expression 6 weeks after vector injection. (B) Confirmation, by sharp-electrode measurement, of light-induced and sus-
tained depolarization in a ReaChR-expressing ventricular tissue slice. (C) Schematic overview of a ReaChR-expressing heart in the Langendorff setup
equipped for electrical stimulation and recording, in which the area of LED illumination and optical mapping are indicated by the blue and black dotted
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..termination is feasible in the intact heart could have an impact on the
development of novel treatment options for cardiac arrhythmias, as
there may be several advantages of biological anti-arrhythmic therapy
over conventional therapy. These advantages could relate to the spe-
cificity of the intervention, which is superb for optogenetics and rela-
tively poor for drugs.10 In addition, optogenetic interventions allow
temporary modulation of electrical function, as opposed to tissue ab-
lation, which results in permanent alteration of the electrical proper-
ties of cardiac tissue.11 Importantly, optogenetic arrhythmia
termination obviates the use of high-voltage electroshocks. These
shocks are not only known to be painful and to cause anxiety and
stress in a significant percentage of patients wearing an ICD2, but also
to cause myocardial tissue damage.3 In theory, these disadvantages
could be avoided if the heart itself would be able to generate, on cue,
the electrical current for arrhythmia termination, as with cardiac
optogenetics. Obviously, many hurdles need to be overcome before
clinical translation can be considered, but the concept of biological
arrhythmia management seems worth further investigation consider-
ing the unique potential benefits.
Our data suggests that APD prolongation plays an important role
in optogenetic arrhythmia termination. Such prolongation has been
associated with destabilization of arrhythmic electrical activity,
thereby favouring its termination.12 However, as the exact mechan-
isms remain incompletely understood, further studies are needed in
order to improve mechanistic insight, including evaluation of the min-
imum requirements for effective optogenetic termination, such as
strength, area, and location of illumination. Moreover, further devel-
opment and optimization of optogenetic tools and light delivery
would help to improve optogenetic termination efficiency and, to-
gether with advances in gene transfer technology, will potentially aid
the translation to in vivo applications.
It is expected that potential in vivo applications are hindered by
poor light penetration, and that therefore only a small fraction of the
total number of light-gated ion channels would be activated.13 An im-
portant finding of this study is that light-induced arrhythmia termin-
ation was already successful by illuminating only a small area of the
epicardial surface. This finding at least suggests that it may not be ne-
cessary to illuminate the whole heart. Hence, the challenging aspect
of illumination might be overcome by focusing the light on a relatively
small, but in terms of arrhythmia maintenance, critical area. In add-
ition, this finding also suggests that regional genetic modification by
local delivery of viral vectors14,15 or optogenetically modified cells
into cardiac tissue may already be sufficient for effective optogenetic
modulation, which would be of practical benefit. Furthermore, as
heart size may play an important role in determining the efficiency of
arrhythmia termination via optogenetics, further studies in larger
hearts are needed.16
Taken together, our study demonstrates that the heart itself is able
to produce an electrical current for arrhythmia termination upon
forced expression of light-gated depolarizing ion channels and their
activation by brief and local epicardial illumination. Such biological ar-
rhythmia termination enables precise and shock-free control over
disturbed cardiac rhythm, allowing normal rhythm to regain.
Although further and more detailed studies are certainly needed, the
findings presented in this brief communication do provide proof-of-
principle for optogenetic termination of arrhythmias in the whole
heart and may thereby pave the way for the design and development
of fundamentally novel strategies of cardiac arrhythmia management.
Supplementary material
Supplementary material is available at European Heart Journal online.
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